{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04863183",
      "OrgStudyIdInfo": {
        "OrgStudyId": "OA-01"
      },
      "Organization": {
        "OrgFullName": "Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Cell Therapy With Cellistem-OA for Symptomatic Knee Osteoarthritis",
      "OfficialTitle": "Cell Therapy for Patients With Symptomatic Knee Osteoarthritis: Phase I / II, Controlled, Randomized and Double-blind Clinical Trial"
    },
    "StatusModule": {
      "StatusVerifiedDate": "April 2021",
      "OverallStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "June 1, 2021",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 31, 2021",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 30, 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "April 20, 2021",
      "StudyFirstSubmitQCDate": "April 23, 2021",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "April 28, 2021",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "April 23, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "April 28, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Martha Ligia Arango Rodríguez",
        "ResponsiblePartyInvestigatorTitle": "Director Technical and Scientific Centro de Terapias Avanzadas Fundación Ofalmológica de Santander",
        "ResponsiblePartyInvestigatorAffiliation": "Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Cells for Cells",
            "CollaboratorClass": "UNKNOWN"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Symptomatic knee osteoarthritis is a serious public health problem in the world, it carries a high personal, social and economic impact. Currently, there are no drugs that modify the natural course of the disease. As analgesic therapy becomes insufficient, more invasive measures are applied, ultimately leading to arthroplasty.\n\nThe scientific community has joined efforts to develop new therapeutic approaches that allow the delay and regeneration of injured tissue in these patients. These include cell therapy with mesenchymal stem cells derived from different sources. Although most of the clinical studies carried out in different parts of the world with this therapy in patients with knee osteoarthritis have shown therapeutic benefit, it is necessary to develop clinical trials with high quality in our population.\n\nThe aim of this project is to evaluate the safety, tolerance and efficacy of Cellistem-OA (biological therapy based on mesenchymal stem cells derived from Wharton's jelly of umbilical cord) in patients with knee osteoarthritis in the Colombian population.\n\nInvestigators proposed to carry out an experimental (clinical trial), randomized, controlled and parallel with 30 participants with knee knee osteoarthritis of the medical complex Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle. The participants will be randomized into two groups: i) 15 patients who will receive a dose of 2 x 106 Cellistem-OA and ii) 15 patients who will receive an active comparator (acetonide of triamcinolone 10mg / mL), which will be administered by intra-articular injection in the superolateral aspect of the knee. The outcomes to be evaluated will be: (i) decrease in joint pain, (ii) increase in joint functionality, (iii) improvement in quality of life and (iv) improvement of articular cartilage. These parameters will be evaluated at weeks 1, 4, 8, 12, 24, 25, 28, 32, 36 and 52 post-treatments. Additionally, local and systemic adverse events will be recorded to establish whether or not there is an association between them and the intervention.",
      "DetailedDescription": "Type of study Controlled, randomized, double-blind clinical trial comparing CELLISTEM-OA and active comparator (triamcinolone acetonide).\n\nStudy population Patients from the Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle who consult the trauma and rheumatology service by knee osteoarthritis. Patients who show interest in participating will be cited to an interview with the researchers where both the objectives and the research procedures will be explained.\n\nSample size The sample size considered are 30 participants distributed in two groups.\n\nGroup 1 (control) active comparator: triamcinolone acetonide (10mg / mL) via intra-articular, 5 cc.\n\nGroup 2 (experimental): CELLISTEM-OA via intra-articular, doses of 2 x 106 cells in 5cc of saline solution.\n\nThe intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments using sterile technique, after cooling the skin with local ice."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Mesenchymal Stem Cells",
          "Knee Osteoarthritis",
          "Cell Therapy"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "Controlled, randomized, double-blind clinical trial comparing CELLISTEM-OA and active comparator (triamcinolone acetonide).",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Triple",
          "DesignMaskingDescription": "The Center for Advanced Therapies will send a pre-filled syringe with the 5 cc of solution without any difference in its external appearance, regardless of the content, according to the previously randomization.",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "30",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Group 1 (control-Triamcinolone acetonide)",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Triamcinolone acetonide (10mg / mL) via intra-articular, 5 cc, one dose (zero time).",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Triamcinolone acetonide"
              ]
            }
          },
          {
            "ArmGroupLabel": "Group 2 (experimental- CELLISTEM-OA)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "CELLISTEM-OA via intra-articular, doses of 2 x 106 mesenchymal stem cells in 5cc of saline solution, one dose (zero time).",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: CELLISTEM-OA"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "CELLISTEM-OA",
            "InterventionDescription": "The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group 2 (experimental- CELLISTEM-OA)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Mesenchymal stem cells"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Triamcinolone acetonide",
            "InterventionDescription": "The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group 1 (control-Triamcinolone acetonide)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Kenacort-A"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Decrease in joint pain",
            "PrimaryOutcomeDescription": "Pain will be measured through visual analog scale (VAS).",
            "PrimaryOutcomeTimeFrame": "12 months"
          },
          {
            "PrimaryOutcomeMeasure": "Increased joint functionality",
            "PrimaryOutcomeDescription": "Joint functionality will be measured through the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).",
            "PrimaryOutcomeTimeFrame": "12 months"
          },
          {
            "PrimaryOutcomeMeasure": "Improvement in the quality of life",
            "PrimaryOutcomeDescription": "Quality of life will be measured through the Short Form 36 Health Survey Questionnaire (SF-36).",
            "PrimaryOutcomeTimeFrame": "12 months"
          },
          {
            "PrimaryOutcomeMeasure": "Imaging improvement of articular cartilage",
            "PrimaryOutcomeDescription": "The improvement of articular cartilage will be evaluated by nuclear magnetic resonance (NMR).",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatients who / with:\n\nOsteoarthritis of the knee.\nKellgren II or III to knee radiography.\n30 to 75 years inclusive.\nPain scale greater than 40 over 100 mm.\nMRI with G I, II or III chondral knee injury with or without stable degenerative meniscal injury.\nStable knee.\nExamination of the rest of the normal limb.\nWillingness to participate in the study for 1 year.\nAbility to understand and willingness to sign the informed consent.\n\nExclusion Criteria:\n\nPatients who / with:\n\nSymptomatic contralateral knee osteoarthritis.\nSignificant knee trauma in the preceding 3 months.\nWound or skin lesion in the knee studied.\nAnatomical valgus greater than 10º.\nAnatomical varus greater than 5º.\nClinically significant joint effusion.\nEdema greater than 20% of the surface of the plateau or condyle in NMR.\nPreviously known alterations in the hip and / or spine.\nPredominant patellofemoral pathology (radiographs with IWANO II osteoarthritis or more).\nAny type of inflammatory arthritis.\nHistory of active infections including HIV, HBV and HCV.\nResults of laboratory tests (hemogram and CRP) outside the normal ranges.\nPresence of fever on day -1 or day 0.\nUse of oral corticosteroids.\nUse of anticoagulants.\nImmunosuppression, uncontrolled diabetes mellitus, hyperthyroidism, psychiatric illnesses\nActive neoplasia or during the preceding 5 years.\nPregnancy or breastfeeding (b-Hcg positive).\nUse of drugs or alcoholism.\nIA injections or knee surgeries in the last 180 days.\nBMI> 35.\nAny type of metallic implant susceptible to displacement with MRI.\nUse of pacemakers.\nHistory of severe allergy or anaphylactic shock.\nSignificant alterations in the evaluation of the initial laboratory tests.\nAny factor that, in the opinion of the investigator, may affect the adequate follow-up of the patient during the study",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "30 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Martha L Arango, PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "(57) 3226816547",
            "CentralContactEMail": "martha.arango@foscal.com.co"
          },
          {
            "CentralContactName": "Omar Amado, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "(57)3108595352",
            "CentralContactEMail": "omaramado85@gmail.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Martha L Arango, PhD",
            "OverallOfficialAffiliation": "Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000010003",
            "ConditionMeshTerm": "Osteoarthritis"
          },
          {
            "ConditionMeshId": "D000020370",
            "ConditionMeshTerm": "Osteoarthritis, Knee"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000001168",
            "ConditionAncestorTerm": "Arthritis"
          },
          {
            "ConditionAncestorId": "D000007592",
            "ConditionAncestorTerm": "Joint Diseases"
          },
          {
            "ConditionAncestorId": "D000009140",
            "ConditionAncestorTerm": "Musculoskeletal Diseases"
          },
          {
            "ConditionAncestorId": "D000012216",
            "ConditionAncestorTerm": "Rheumatic Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M12078",
            "ConditionBrowseLeafName": "Osteoarthritis",
            "ConditionBrowseLeafAsFound": "Osteoarthritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21321",
            "ConditionBrowseLeafName": "Osteoarthritis, Knee",
            "ConditionBrowseLeafAsFound": "Knee Osteoarthritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3628",
            "ConditionBrowseLeafName": "Arthritis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9773",
            "ConditionBrowseLeafName": "Joint Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11249",
            "ConditionBrowseLeafName": "Musculoskeletal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14197",
            "ConditionBrowseLeafName": "Rheumatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5475",
            "ConditionBrowseLeafName": "Collagen Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000014221",
            "InterventionMeshTerm": "Triamcinolone"
          },
          {
            "InterventionMeshId": "D000014222",
            "InterventionMeshTerm": "Triamcinolone Acetonide"
          },
          {
            "InterventionMeshId": "C000005900",
            "InterventionMeshTerm": "Triamcinolone hexacetonide"
          },
          {
            "InterventionMeshId": "C000030262",
            "InterventionMeshTerm": "Triamcinolone diacetate"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000000893",
            "InterventionAncestorTerm": "Anti-Inflammatory Agents"
          },
          {
            "InterventionAncestorId": "D000005938",
            "InterventionAncestorTerm": "Glucocorticoids"
          },
          {
            "InterventionAncestorId": "D000006728",
            "InterventionAncestorTerm": "Hormones"
          },
          {
            "InterventionAncestorId": "D000006730",
            "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000007166",
            "InterventionAncestorTerm": "Immunosuppressive Agents"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000004791",
            "InterventionAncestorTerm": "Enzyme Inhibitors"
          },
          {
            "InterventionAncestorId": "D000045504",
            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M21013",
            "InterventionBrowseLeafName": "Pharmaceutical Solutions",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M16126",
            "InterventionBrowseLeafName": "Triamcinolone",
            "InterventionBrowseLeafAsFound": "Increased",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M16127",
            "InterventionBrowseLeafName": "Triamcinolone Acetonide",
            "InterventionBrowseLeafAsFound": "Albumin",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M237968",
            "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
            "InterventionBrowseLeafAsFound": "Albumin",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M209570",
            "InterventionBrowseLeafName": "Triamcinolone diacetate",
            "InterventionBrowseLeafAsFound": "Albumin",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M3369",
            "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M8199",
            "InterventionBrowseLeafName": "Glucocorticoids",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M8941",
            "InterventionBrowseLeafName": "Hormones",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M8940",
            "InterventionBrowseLeafName": "Hormone Antagonists",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9364",
            "InterventionBrowseLeafName": "Immunosuppressive Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "PhSol",
            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infl",
            "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
          }
        ]
      }
    }
  }
}